(Q57570627)

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Incidence and survival for cancer in children and young adults in the North of England, 1968-1995: a report from the Northern Region Young Persons' Malignant Disease Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Incidence of biopsy-proven bone tumors in children: a report based on the Dutch pathology registration "PALGA".

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Results of diagnostic review in pediatric bone tumors and tumorlike lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Utilization of positron emission tomography in the management of patients with sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Prognostic factors in localized extremity osteosarcoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Ewing sarcoma: prognostic criteria, outcomes and future treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Periosteal osteosarcoma--a European review of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Periosteal osteosarcoma: a single-institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Common musculoskeletal tumors of childhood and adolescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Current strategies of chemotherapy in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Delaying surgery with chemotherapy for osteosarcoma of the extremities

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

The role of interferons in the treatment of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Complexities in interpretation of osteosarcoma clinical trial results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Osteosarcoma over the age of forty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22)(q24;q12).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Variability of EWS chimaeric transcripts in Ewing tumours: a comparison of clinical and molecular data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Molecular diagnosis of Ewing sarcoma family of tumors: a comparative analysis of 560 cases with FISH and RT-PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Treatment strategies for metastatic Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Ewing's sarcoma family of tumors: current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Imaging evaluation of the response of high-grade osteosarcoma and Ewing sarcoma to chemotherapy with emphasis on dynamic contrast-enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

The clinical approach towards chondrosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

The clinical management of chondrosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Radiotherapeutic factors in the management of cervical-basal chordomas and chondrosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Diagnostic imaging of solitary tumors of the spine: what to do and say.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Current surgical outcomes for cranial base chordomas: cohort study of 95 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Chordomas of the skull base and cervical spine: clinical outcomes associated with a multimodal surgical resection combined with proton-beam radiation in 40 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Operative management of sacral chordoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Posterior-only approach for en bloc sacrectomy: clinical outcomes in 36 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Phase II study of imatinib in advanced chordoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256

Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU256